gastroesophageal reflux disease (GERD) Segmentation: Document how Swiss general practitioners (GPs) allocate their GERD patients to the three GERD patient segments

Study identifier:NIS-GCH-NEX-2007/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

GERD Segmentation: Document how Swiss GPs allocate their GERD patients to the three GERD patient segments

Medical condition

GERD

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

2912

Study type

Observational

Age

12 Years +

Date

Study Start Date: 01 Feb 2008

Primary Completion Date: 01 Aug 2008

Study Completion Date: 01 Aug 2008

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Aarau, Switzerland

Arms	Assigned Interventions
Treated GERD pts Previously diagnosed GERD patients on treatment in Switzerland	-

"There is no result for the study"

Documents available

CSR-NIS-GCH-NEX-2007-1.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Switzerland Clinical Study Information

41-41-725-7575

madeleine.billeter@astrazeneca.com